106 related articles for article (PubMed ID: 38757460)
1. Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan.
Tada Y; Soliman AM; Ishii K; Sakuma R; Pinter A; Davis M; Nunag D; Buessing M; Puig L; Imafuku S
Exp Dermatol; 2024 May; 33(5):e15067. PubMed ID: 38757460
[TBL] [Abstract][Full Text] [Related]
2. Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan.
Tada Y; Soliman AM; Ishii K; Sakuma R; Puig L; Davis M; Nunag D; Pinter A; Imafuku S
Dermatol Ther (Heidelb); 2024 Jan; 14(1):99-114. PubMed ID: 38019410
[TBL] [Abstract][Full Text] [Related]
3. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
[TBL] [Abstract][Full Text] [Related]
4. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
[TBL] [Abstract][Full Text] [Related]
5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
6. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
[TBL] [Abstract][Full Text] [Related]
7. Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial.
Blauvelt A; Lomaga M; Burge R; Zhu B; Shen W; Shrom D; Dossenbach M; Pinter A
J Dermatolog Treat; 2020 Mar; 31(2):141-146. PubMed ID: 30799638
[No Abstract] [Full Text] [Related]
8. Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States.
Wu JJ; Patel M; Zeng F; Huang A; Pan X; Cao Y; Chen N; Photowala H; Garg V; Crowley J
J Dermatolog Treat; 2023 Dec; 34(1):2200869. PubMed ID: 37025014
[TBL] [Abstract][Full Text] [Related]
9. Japanese guidance for use of biologics for psoriasis (the 2019 version).
Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
[TBL] [Abstract][Full Text] [Related]
10. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
[TBL] [Abstract][Full Text] [Related]
11. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study.
Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A
Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754
[TBL] [Abstract][Full Text] [Related]
12. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
[TBL] [Abstract][Full Text] [Related]
14. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
[TBL] [Abstract][Full Text] [Related]
15. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
[TBL] [Abstract][Full Text] [Related]
16. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
Sruamsiri R; Iwasaki K; Tang W; Mahlich J
BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
[TBL] [Abstract][Full Text] [Related]
18. Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Armstrong A; González-Cantero A; Khattri S; Muzy G; Malatestinic WN; Lampropoulou A; Feely M; See SK; Mert C; Blauvelt A
Dermatol Ther (Heidelb); 2024 Apr; 14(4):933-952. PubMed ID: 38521874
[TBL] [Abstract][Full Text] [Related]
19. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
Blauvelt A; Shi N; Zhu B; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Murage MJ
J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
